Candel Therapeutics Inc (NASDAQ: CADL) kicked off on Tuesday, up 3.70% from the previous trading day, before settling in for the closing price of $5.4. Over the past 52 weeks, CADL has traded in a range of $3.79-$14.60.
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -43.86%. While this was happening, its average annual earnings per share was recorded 75.90%. With a float of $37.81 million, this company’s outstanding shares have now reached $54.89 million.
The extent of productivity of a business whose workforce counts for 38 workers is very important to gauge.
Candel Therapeutics Inc (CADL) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Candel Therapeutics Inc is 31.12%, while institutional ownership is 37.56%. The most recent insider transaction that took place on Jul 28 ’25, was worth 6,540. In this transaction Chief Medical Officer of this company sold 937 shares at a rate of $6.98, taking the stock ownership to the 52,493 shares. Before that another transaction happened on Jun 30 ’25, when Company’s Chief Medical Officer sold 781 for $5.04, making the entire transaction worth $3,936. This insider now owns 52,493 shares in total.
Candel Therapeutics Inc (CADL) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.28 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 75.90% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 38.37% during the next five years compared to -43.86% drop over the previous five years of trading.
Candel Therapeutics Inc (NASDAQ: CADL) Trading Performance Indicators
Take a look at Candel Therapeutics Inc’s (CADL) current performance indicators. Last quarter, stock had a quick ratio of 7.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.69, a number that is poised to hit -0.19 in the next quarter and is forecasted to reach -0.90 in one year’s time.
Technical Analysis of Candel Therapeutics Inc (CADL)
The latest stats from [Candel Therapeutics Inc, CADL] show that its last 5-days average volume of 0.64 million was inferior to 0.99 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 30.15%.
During the past 100 days, Candel Therapeutics Inc’s (CADL) raw stochastic average was set at 40.43%, which indicates a significant increase from 32.67% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.40 in the past 14 days, which was higher than the 0.35 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $5.45, while its 200-day Moving Average is $6.20. Now, the first resistance to watch is $5.83. This is followed by the second major resistance level at $6.06. The third major resistance level sits at $6.27. If the price goes on to break the first support level at $5.39, it is likely to go to the next support level at $5.18. The third support level lies at $4.95 if the price breaches the second support level.
Candel Therapeutics Inc (NASDAQ: CADL) Key Stats
The company with the Market Capitalisation of 307.41 million has total of 54,895K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -55,180 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -4,800 K.
